QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.134593v1 jpet.107.134593v2 324/3/1163    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shroads, A. L. Articles by Stacpoole, P. W. Search for Related Content PubMed PubMed Citation Articles by Shroads, A. L. Articles by Stacpoole, P. W.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Age-Dependent Kinetics and Metabolism of Dichloroacetate: Possible Relevance to Toxicity

Departments of Medicine (A.L.S., X.G., H.-P.L., P.W.S.), Medicinal Chemistry (V.D., M.O.J.), and Biochemistry and Molecular Biology (P.W.S.), University of Florida Colleges of Medicine and Pharmacy, and the General Clinical Research Center (P.W.S.), University of Florida, Gainesville, Florida

Dichloroacetate (DCA) is an investigational drug for certain metabolic diseases. It is biotransformed principally by the -1 family isoform of glutathione transferase (GSTz1), also known as maleylacetoacetate isomerase (MAAI), which catalyzes the penultimate step in tyrosine catabolism. DCA causes a reversible peripheral neuropathy in several species, including humans. However, recent clinical trials indicate that adults are considerably more susceptible to this adverse effect than children. We evaluated the kinetics and biotransformation of DCA and its effects on tyrosine metabolism in nine patients treated for 6 months with 25 mg/kg/day and in rats treated for 5 days with 50 mg/kg/day. We also measured the activity and expression of hepatic GSTz1/MAAI. Chronic administration of DCA causes a striking age-dependent decrease in its plasma clearance and an increase in its plasma half-life in patients and rats. Urinary excretion of unchanged DCA in rats increases with age, whereas oxalate, an end product of DCA metabolism, shows the opposite trend. Low concentrations of monochloroacetate (MCA), which is known to be neurotoxic, increase as a function of age in the urine of dosed rats. MCA was detectable in plasma only of older animals. Hepatic GSTz1/MAAI-specific activity was inhibited equally by DCA treatment among all age groups, whereas plasma and urinary levels of maleylacetone, a natural substrate for this enzyme, increased with age. We conclude that age is an important variable in the in vivo metabolism and elimination of DCA and that it may account, in part, for the neurotoxicity of this compound in humans and other species.

Address correspondence to: Dr. Peter W. Stacpoole, P.O. Box 100226, J. Hillis Miller Health Science Center, Gainesville, FL 32610. E-mail: peter.stacpoole{at}medicine.ufl.edu

This article has been cited by other articles:

				R. M. Wynn, M. Kato, J. L. Chuang, S.-C. Tso, J. Li, and D. T. Chuang Pyruvate Dehydrogenase Kinase-4 Structures Reveal a Metastable Open Conformation Fostering Robust Core-free Basal Activity J. Biol. Chem., September 12, 2008; 283(37): 25305 - 25315. [Abstract] [Full Text] [PDF]